Experimental Drug Yields Dramatic Weight Loss
The New York Times • • business
Key Points:
- Eli Lilly announced that its experimental drug retatrutide helped participants lose significantly more weight than existing obesity medications in a large clinical trial.
- Among the heaviest patients, weight loss results were comparable to those achieved with gastric bypass surgery, a standard treatment for severe obesity.
- Retatrutide is considered the most potent drug so far in the new generation of obesity treatments, with some trial participants reportedly stopping use due to rapid weight loss.
- The drug's effectiveness and safety have yet to be confirmed through peer-reviewed publication, and it often causes gastrointestinal side effects at higher doses, leading some patients to discontinue use.
- If long-term effects remain consistent, retatrutide could redefine the potential of weight loss medications in treating obesity.